Aptose Biosciences to Host Key Opinion Leader Event Present at BIO CEO & Investor Conference
January 29, 2020 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Biosciences to Present at Biotech Showcase™ 2020 Conference
January 07, 2020 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Announces Closing of Public Offering of Common Shares
December 19, 2019 16:02 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced...
Aptose Announces Pricing of Public Offering of Common Shares
December 17, 2019 08:00 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced...
Aptose Presents New Preclinical CG-806 Data at the 2019 ASH Annual Meeting
December 09, 2019 11:00 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...
Aptose Presents Highlights From Corporate Event At ASH
December 07, 2019 11:00 ET
|
Aptose Biosciences, Inc.
SAN DIEGO, TORONTO and ORLANDO, Fla., Dec. 07, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) released highlights from a corporate event and clinical update today held at...
Aptose Appoints Rafael Bejar, M.D., Ph.D., as Chief Medical Officer
December 04, 2019 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the...
Aptose to Present at 31st Annual Piper Jaffray Healthcare Conference
December 02, 2019 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Reports Results for the Third Quarter Ended September 30, 2019
November 05, 2019 16:02 ET
|
Aptose Biosciences, Inc.
CG-806 Mutation Agnostic FLT3/BTK Inhibitor and APTO-253 MYC Inhibitor Safely Dose Escalate CLL Patient Treated with Second Dose Level of CG-806 Shows Evidence of Clinical Response Conference Call...
Aptose To Release Third Quarter Ended September 30, 2019 Financial Results and Hold Conference Call on November 5, 2019
October 22, 2019 07:00 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the...